Medication info
Janux XR Controlled-release Tablets 50/750 mg (Sitagliptin, Metformin)

Janux XR Controlled-release Tablets 50/750 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›750mg / 1 tablet
Manufacturer / importer
Sinil Pharmaceutical Co., Ltd.
Appearance
Bright green, oval-shaped, biconvex controlled-release film-coated tablets
Packaging
28 tablets/bottle, 30 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300019 · Approved 2023.01.02 · Insurance code 649703050

Summary

Main use
Improves blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). The dose of this drug 100/1000 mg extended-release tablet is 1 tablet once daily. Patients taking this drug 50/500 mg extended-release tablet, 50/750 mg extended-release tablet, or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their existing doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily based on their existing metformin dose may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial metformin dose should take into account the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used).

Ingredients

Manufacturer
Sinil Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes

View approved original text

This medication is suitable for helping blood sugar control in patients with Type 2 diabetes when used in conjunction with diet and exercise therapy. The combination of sitagliptin and metformin effectively improves blood sugar levels, aiding in diabetes management. As a result, blood sugar is stably controlled, which can contribute to the prevention of complications.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). The dose of this drug 100/1000 mg extended-release tablet is 1 tablet once daily. Patients taking this drug 50/500 mg extended-release tablet, 50/750 mg extended-release tablet, or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their existing doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily based on their existing metformin dose may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial metformin dose should take into account the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom the Drug Must Not Be Used).

Precautions

This medication contains sitagliptin and metformin, both of which are diabetes treatments that assist in blood sugar control. Firstly, sitagliptin can rarely cause severe allergic reactions; therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, you must immediately stop taking this medication and consult a doctor. Furthermore, acute pancreatitis can occur, so if there are symptoms such as abdominal pain, nausea, or vomiting, you should promptly inform your healthcare provider. Metformin can rarely cause lactic acidosis, a serious metabolic disorder that results from excessive accumulation of lactate in the body. Symptoms such as fatigue, muscle pain, difficulty breathing, or abdominal pain warrant an immediate visit to the hospital. Particularly, it is safest not to take this medication if you have poor kidney function, decreased liver function, severe infections, or are in a state of dehydration. This medication should not be administered to patients with moderate to severe renal impairment, acute heart failure or myocardial infarction, patients with severe infections, or women who are pregnant or breastfeeding. During treatment, regular monitoring of kidney function and blood tests should be conducted, and periodically checking Vitamin B12 levels is advisable. In addition, excessive alcohol consumption should be avoided while taking this medication, and caution is needed for intense exercise or irregular meal intake, which may increase the risk of hypoglycemia or lactic acidosis. If you are to undergo surgery or procedures using iodine contrast agents, you must temporarily discontinue this medication, and resume it only after confirming that kidney function is normal. Finally, there may be interactions when this medication is taken with other blood glucose-lowering agents, certain diuretics, or antihypertensive drugs, so be sure to inform your healthcare provider about any other medications you are taking.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe arthralgia accompanied by disability, blistering dermatosis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, rash, urticaria, cutaneous vasculitis, elevated liver enzymes, acute renal failure, hypoglycemic episodes, peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the medication's effectiveness over time.

Appearance and packaging

Appearance

Bright green, oval-shaped, biconvex controlled-release film-coated tablets

Package unit

28 tablets/bottle, 30 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.